This inventor holds 45 USPTO granted patents and 47 published patent applications and 3 EPO patents, primarily in Genetically Modified Animals. Top assignees: Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Eucure (Beijing) Biopharma Co., Ltd., Biocytogen Jiangsu Co., Ltd.. Active years: 2019-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
33 out of 33 
8 out of 8 
4 out of 4 Years Active: 2019-2025
Areas of Expertise:
Title: Innovations in Cancer Treatment by Yuelei Shen
Introduction
Yuelei Shen, a prominent inventor based in Beijing, China, has made significant contributions to the field of oncology through his innovative research and development. With an impressive portfolio of 44 patents, Shen is dedicated to advancing medical treatments that enhance patient outcomes and tackle complex diseases such as cancer.
Latest Patents
Among Shen's latest patents are groundbreaking discoveries regarding anti-PD-1 antibodies and anti-CD40 antibodies. His patent related to anti-PD-1 antibodies outlines novel methods of treating cancer by targeting the Programmed Cell Death Protein 1, a critical component in the regulation of immune responses. Additionally, his work on anti-CD40 antibodies involves innovative approaches to harness the immune system in combating tumors, demonstrating his commitment to developing effective cancer therapies.
Career Highlights
Yuelei Shen has an impressive career marked by his tenure at well-respected organizations. He has worked with Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and Eucure (Beijing) Biopharma Co., Ltd., where he played pivotal roles in research and development. His experience in these companies has allowed him to refine his expertise in biopharmaceutical innovations, particularly in antibody development for cancer treatment.
Collaborations
Throughout his career, Shen has collaborated with esteemed colleagues in the field, including Yanan Guo and Yang Bai. These partnerships have contributed to the successful translation of research into practical applications, ensuring that cutting-edge therapies reach those in need.
Conclusion
Yuelei Shen's contributions to the medical field, particularly in oncology, underscore his role as a leading inventor. With a strong focus on developing innovative treatments such as anti-PD-1 and anti-CD40 antibodies, Shen continues to make strides that could potentially change the landscape of cancer therapy, emphasizing the importance of research and collaboration in the pursuit of healthcare advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile